(FM) Oncología
Departamento académico
Hospital Virgen del Camino
Pamplona, EspañaHospital Virgen del Camino -ko ikertzaileekin lankidetzan egindako argitalpenak (44)
2023
2022
-
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
British Journal of Cancer, Vol. 126, Núm. 8, pp. 1168-1177
2021
-
A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets
Journal of Personalized Medicine, Vol. 11, Núm. 6
-
Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis
Therapeutic Advances in Medical Oncology, Vol. 13
-
Prevalence of nodal involvement in rectal cancer after chemoradiotherapy
The British journal of surgery, Vol. 108, Núm. 10, pp. 1251-1258
-
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149
-
Understanding lag-3 signaling
International Journal of Molecular Sciences, Vol. 22, Núm. 10
2020
-
Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
Gynecologic Oncology Reports, Vol. 33
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
-
PD-L1 in systemic immunity: Unraveling its contribution to PD-1/PD-L1 blockade immunotherapy
International Journal of Molecular Sciences, Vol. 21, Núm. 16, pp. 1-17
-
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
International Journal of Molecular Sciences, Vol. 21, Núm. 7
-
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Oncologist, Vol. 25, Núm. 9, pp. 745-e1265
2019
-
Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
British Journal of Clinical Pharmacology, Vol. 85, Núm. 8, pp. 1670-1683
-
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544
-
PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer
International Journal of Molecular Sciences, Vol. 20, Núm. 7
-
TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies
Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631
2018
-
A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis
Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
-
Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia
2017
-
Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study
Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 969-975